FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions relates to field of medicine and pharmaceutics. As antagonist of neuropiline-2 applied is antibody against Nrp2B, or its antigen-binding fragment, which contains sequences of areas, which define complementarity, (CDR) of variable domains of light and/or heavy chain of antibody YW68.4.2 or antibody YW68.4.2.36, or version of claimed antibody or claimed antigen-binding fragment, where amino acid sequence Fab of YW68.4.2 of antibody fragment is shown in figure 10A and amino acid sequence Fab of YW68.4.2.36 of antibody fragment is shown in figure 10B.
EFFECT: group of inventions makes it possible to increase efficiency of prevention and treatment of tumour metastases.
21 cl, 13 dwg, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTI-panNrp ANTIBODY (VERSIONS) | 2007 |
|
RU2454427C2 |
| METHOD FOR PREDICTION OF RECURRENCE IN PATIENTS WITH BASAL CELL CARCINOMA OF SKIN AFTER SURGICAL REMOVAL OF TUMOUR | 2024 |
|
RU2823211C1 |
| ACTIVE ANGIOGENESIS-PREVENTING IMMUNETHERAPY | 2003 |
|
RU2329824C2 |
| ALK1 ANTAGONISTS AND THEIR APPLICATION IN THE TREATMENT OF KIDNEY-CELLULAR CARCINOMA | 2013 |
|
RU2633638C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING AS AN ACTIVE INGREDIENT A FUSED PROTEIN IN WHICH A TUMOR-PENETRATING PEPTIDE AND AN ANTIANGIOGENIC AGENT ARE FUSED FOR PREVENTING AND TREATING CANCER OR ANGIOGENESIS-RELATED DISEASES | 2016 |
|
RU2727238C2 |
| POLYSPECIFIC ANTIBODIES | 2009 |
|
RU2547596C2 |
| INHIBITION OF DISSEMINATION OF TUMOUR USING Bv8 OR G-CSF ANTAGONISTS | 2010 |
|
RU2567803C2 |
| COMPOSITIONS OF HUMANISED NOTCH FUSED PROTEINS AND METHODS OF TREATING | 2008 |
|
RU2532830C2 |
| METHODS FOR TREATMENT OF TUMORS AND METASTASIS USING COMBINATION OF ANTI-ANGIOGENIC THERAPY AND IMMUNOTHERAPY | 2000 |
|
RU2236251C2 |
| DLL4 ANTIBODIES AND METHODS OF APPLICATION THEREOF | 2007 |
|
RU2415869C2 |
